NCT00163592View on ClinicalTrials.gov

Post-Marketing Surveillance of TISSUCOL for Hemostasis in Subjects Undergoing Vascular Reconstruction With Polytetrafluoroethylene (PTFE) Prosthesis

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

February 29, 2004

Conditions

Femoral Vascular Anastomosis

Interventions

DRUG

Tissucol®

PROCEDURE

Control: Conventional treatment, i.e. compression with swabs

Trial Locations (5)

5020

General Hospital (AKH) Salzburg, Salzburg

6020

Landeskrankenhaus Innsbruck, Innsbruck

39120

University Clinics of Magdeburg, Department of Vascular Surgery, Magdeburg

71229

Leonberg Hospital, Department of Vascular Surgery, Leonberg

90340

Klinikum Nürnberg Süd, Department of Vascular Surgery, Nuremberg

All Listed Sponsors

lead

Baxter Healthcare Corporation

INDUSTRY

NCT00163592 - Post-Marketing Surveillance of TISSUCOL for Hemostasis in Subjects Undergoing Vascular Reconstruction With Polytetrafluoroethylene (PTFE) Prosthesis | Biotech Hunter | Biotech Hunter